An aptamer targets HBV core protein and suppresses HBV replication in HepG2.2.15 cells

Zhang,Zuowei; Zhang,Jun; Pei,Xiaoyu; Zhang,Qi; Lu,Bin; Zhang,Xiaojiao; Liu,Jie

doi:10.3892/ijmm.2014.1908

An aptamer targets HBV core protein and suppresses HBV replication in HepG2.2.15 cells

Authors:
- Zuowei Zhang
- Jun Zhang
- Xiaoyu Pei
- Qi Zhang
- Bin Lu
- Xiaojiao Zhang
- Jie Liu
View Affiliations

Affiliations: Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai, P.R. China
Published online on: August 19, 2014 https://doi.org/10.3892/ijmm.2014.1908
Pages: 1423-1429

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatitis B virus (HBV)-related hepatitis is a major health concern worldwide. As current anti-HBV therapies are limited, it is essential to develop new strategies. Aptamer, a newly developed adaptive molecule (single-strand DNA or RNA also known as nucleotide antibody), is a new strategy for clinical diagnosis and therapy due to its high affinity and specificity. In the present study, by systematic evolution of ligand by exponential enrichment (SELEX), aptamers were screened against the core protein of HBV (HBc) from a random ssDNA library. Quantitative PCR (qPCR) results showed that the binding proportions of the SELEX-enriched aptamer pools were increased with the SELEX rounds, until round seven. Thus, the pool of round seven was cloned. Following the sequence analysis of a total of 90 clones by Macaw software, five aptamer candidates were selected and their affinity to HBc was tested by dot blot. Apt.No.28, which had sequence replicates in the clones, was shown to have a high affinity. Furthermore, by agarose gel electrophoresis-capillary transfer-blotting and qPCR, Apt.No.28 was shown to inhibit the assembly of the nucleocapsid, reducing extracellular HBV DNA whose synthesis relied on the formation of the nucleocapsid, indicating its role in suppressing HBV replication. The results provided a new ideal targeting molecule and may facilitate the strategy for targeted therapy as well as drug development of HBV-related diseases.

View Figures

View References

1	Ma X, Lin C and Zhen W: Cancer care in China: a general review. Biomed Imaging Interv J. 4:e392008.PubMed/NCBI
2	Vigano M and Lampertico P: Antiviral drugs for HBV liver disease. Expert Opin Biol Ther. 11:285–300. 2011. View Article : Google Scholar : PubMed/NCBI
3	Yan H, Zhong G, Xu G, et al: Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 1:e000492012.PubMed/NCBI
4	Roseman AM, Berriman JA, Wynne SA, Butler PJ and Crowther RA: A structural model for maturation of the hepatitis B virus core. Proc Natl Acad Sci USA. 102:15821–15826. 2005. View Article : Google Scholar : PubMed/NCBI
5	Deres K, Schroder CH, Paessens A, et al: Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science. 299:893–896. 2003. View Article : Google Scholar : PubMed/NCBI
6	Kulbachinskiy AV: Methods for selection of aptamers to protein targets. Biochemistry (Moscow). 72:1505–1518. 2007. View Article : Google Scholar : PubMed/NCBI
7	Sefah K, Shangguan D, Xiong X, O’Donoghue MB and Tan W: Development of DNA aptamers using Cell-SELEX. Nat Protoc. 5:1169–1185. 2010. View Article : Google Scholar : PubMed/NCBI
8	Chakravarthy U, Adamis AP, Cunningham ETJ, et al: Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 113:1508.e1501–1508.e1525. 2006.PubMed/NCBI
9	Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR and Adamis AP: Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 5:123–132. 2006. View Article : Google Scholar : PubMed/NCBI
10	Ramalingam D, Duclair S, Datta SA, Ellington A, Rein A and Prasad VR: RNA aptamers directed to human immunodeficiency virus type 1 Gag polyprotein bind to the matrix and nucleocapsid domains and inhibit virus production. J Virol. 85:305–314. 2011. View Article : Google Scholar : PubMed/NCBI
11	Kikuchi K, Umehara T, Fukuda K, Kuno A, Hasegawa T and Nishikawa S: A hepatitis C virus (HCV) internal ribosome entry site (IRES) domain III-IV-targeted aptamer inhibits translation by binding to an apical loop of domain IIId. Nucleic Acids Res. 33:683–692. 2005. View Article : Google Scholar : PubMed/NCBI
12	Kikuchi K, Umehara T, Nishikawa F, Fukuda K, Hasegawa T and Nishikawa S: Increased inhibitory ability of conjugated RNA aptamers against the HCV IRES. Biochem Biophys Res Commun. 386:118–123. 2009. View Article : Google Scholar : PubMed/NCBI
13	Chen F, Hu Y, Li D, Chen H and Zhang XL: CS-SELEX generates high-affinity ssDNA aptamers as molecular probes for hepatitis C virus envelope glycoprotein E2. PLoS One. 4:e81422009. View Article : Google Scholar : PubMed/NCBI
14	Neff CP, Zhou J, Remling L, et al: An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4⁺ T cell decline in humanized mice. Sci Transl Med. 3:66ra662011.PubMed/NCBI
15	Zhou J, Li H, Li S, Zaia J and Rossi JJ: Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther. 16:1481–1489. 2008. View Article : Google Scholar : PubMed/NCBI
16	Liu J, Yang Y, Hu B, et al: Development of HBsAg-binding aptamers that bind HepG2.2.15 cells via HBV surface antigen. Virol Sin. 25:27–35. 2010. View Article : Google Scholar : PubMed/NCBI
17	Feng H, Beck J, Nassal M and Hu KH: A SELEX-screened aptamer of human hepatitis B virus RNA encapsidation signal suppresses viral replication. PLoS One. 6:e278622011. View Article : Google Scholar : PubMed/NCBI
18	Ray P and White RR: Aptamers for targeted drug delivery. Pharmaceuticals. 3:1761–1778. 2010. View Article : Google Scholar
19	Jun-Bin S, Zhi C, Wei-Qin N and Jun F: A quantitative method to detect HBV cccDNA by chimeric primer and real-time polymerase chain reaction. J Virol Methods. 112:45–52. 2003. View Article : Google Scholar : PubMed/NCBI
20	Zhang W, Ke W, Wu SS, et al: An adenovirus-delivered peptide aptamer C1-1 targeting the core protein of hepatitis B virus inhibits viral DNA replication and production in vitro and in vivo. Peptides. 30:1816–1821. 2009. View Article : Google Scholar : PubMed/NCBI
21	Calvert J and Summers J: Two regions of an avian hepadnavirus RNA pregenome are required in cis for encapsidation. J Virol. 68:2084–2090. 1994.PubMed/NCBI
22	Lu B, Wang J, Zhang J, et al: Screening and verification of ssDNA aptamers targeting human hepatocellular carcinoma. Acta Biochim Biophys Sin (Shanghai). 46:128–135. 2014. View Article : Google Scholar : PubMed/NCBI
23	Devi U and Locarnini S: Hepatitis B antivirals and resistance. Curr Opin Virol. 3:495–500. 2013. View Article : Google Scholar : PubMed/NCBI
24	Ferapontova EE and Gothelf KV: Recent advances in electrochemical aptamer-based sensors. Curr Org Chem. 15:498–505. 2011. View Article : Google Scholar
25	Chu TC, Marks JW III, Lavery LA, et al: Aptamer: toxin conjugates that specifically target prostate tumor cells. Cancer Res. 66:5989–5992. 2006. View Article : Google Scholar : PubMed/NCBI
26	Wang JC, Dhason MS and Zlotnick A: Structural organization of pregenomic RNA and the carboxy-terminal domain of the capsid protein of hepatitis B virus. PLoS Pathog. 8:e10029192012. View Article : Google Scholar : PubMed/NCBI
27	Vanlandschoot P, Van Houtte F, Serruys B and Leroux-Roels G: The arginine-rich carboxy-terminal domain of the hepatitis B virus core protein mediates attachment of nucleocapsids to cell-surface-expressed heparan sulfate. J Gen Virol. 86:75–84. 2005. View Article : Google Scholar : PubMed/NCBI
28	Jammeh S, Tavner F, Watson R, Thomas HC and Karayiannis P: Effect of basal core promoter and pre-core mutations on hepatitis B virus replication. J Gen Virol. 89:901–909. 2008. View Article : Google Scholar : PubMed/NCBI
29	Guo H, Jiang D, Zhou T, Cuconati A, Block TM and Guo JT: Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation. J Virol. 81:12472–12484. 2007. View Article : Google Scholar : PubMed/NCBI
30	Schmitz A, Schwarz A, Foss M, et al: Nucleoporin 153 arrests the nuclear import of hepatitis B virus capsids in the nuclear basket. PLoS Pathog. 6:e10007412010. View Article : Google Scholar : PubMed/NCBI
31	Masri HP and Cornelissen CN: Specific ligand binding attributable to individual epitopes of gonococcal transferrin binding protein A. Infect Immun. 70:732–740. 2002. View Article : Google Scholar : PubMed/NCBI
32	Yamada N and Tanoue E: Detection and partial characterization of dissolved glycoproteins in oceanic waters. Limnol Oceanogr. 48:1037–1048. 2003. View Article : Google Scholar
33	Tomai E, Butz K, Lohrey C, von Weizsacker F, Zentgraf H and Hoppe-Seyler F: Peptide aptamer-mediated inhibition of target proteins by sequestration into aggresomes. J Biol Chem. 281:21345–21352. 2006. View Article : Google Scholar : PubMed/NCBI
34	Butz K, Denk C, Fitscher B, et al: Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity. Oncogene. 20:6579–6586. 2001. View Article : Google Scholar : PubMed/NCBI